Jeffrey Quinn is the Associate Director of Off-Target Biology at Beam Therapeutics in Cambridge, MA, where he leads off-target studies for CRISPR-based gene editing therapeutic programs. Previously, he has worked on developing high-throughput mammalian genome engineering platform technologies. He completed his postdoctoral training in the laboratory of Dr. Jonathan Weissman at the University of California, San Francisco. There, as a Kirschstein National Research Service Fellow, he developed and deployed CRISPR-empowered tools for measuring single-cell lineages in cancer and development. He holds a Ph.D. and M.S. in Bioengineering from Stanford University. His doctoral research in Dr. Howard Chang’s laboratory focused on developing NGS-enabled tools for studying chromatin and the structure and function of noncoding RNAs. He earned his bachelor’s degree in biological engineering at the Massachusetts Institute of Technology (MIT), where he studied DNA damage.